Cycloserine/lurasidone - NeuroRx

Drug Profile

Cycloserine/lurasidone - NeuroRx

Alternative Names: Cyclurad; Lurasidone/cycloserine - NeuroRx; NRX-101

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator NeuroRX
  • Class Isoindoles; Isoxazoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action Glycine NMDA-associated agonists; Serotonin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bipolar depression

Most Recent Events

  • 18 Oct 2016 NeuroRx receives patent allowance for cycloserine/lurasidone in USA
  • 27 May 2016 NeuroRx completes phase II trial in Bipolar depression in USA (PO)
  • 16 Dec 2015 NeuroRx intends to file an IND application with the US FDA for a phase II/III trial in first quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top